An open-label, randomized, three-period, six-sequence crossover study to evaluate bioequivalence of three olanzapine containing tablet formulations in health subjects.

Trial Profile

An open-label, randomized, three-period, six-sequence crossover study to evaluate bioequivalence of three olanzapine containing tablet formulations in health subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development
    • 11 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top